Literature DB >> 28393326

Psychiatric Symptoms in Patients with Cushing's Syndrome: Prevalence, Diagnosis and Management.

Alicia Santos1,2, Eugenia Resmini3,4, Juan Carlos Pascual5,2, Iris Crespo1,2, Susan M Webb1,2.   

Abstract

Cushing's syndrome (CS) results from chronic exposure to cortisol excess, produced by the adrenal cortex. Hypercortisolism predisposes to psychiatric and neurocognitive disorders, mainly to depression and anxiety disorders. Screening tools to identify psychiatric symptoms are available for clinicians in their daily practice, although a specific diagnosis should be performed by specialists. Even if psychiatric symptoms improve after remission of hypercortisolism, complete recovery may not be achieved. Given the burden of these symptoms, psychiatric or psychological monitoring and treatment should be offered through all phases of CS, with a multidisciplinary approach. The aim of this article is to review data on the prevalence, diagnosis and management of psychiatric symptoms seen in patients with CS and to propose therapeutic approaches that may be followed in clinical practice. The prevalence of different psychiatric disorders has been described in both the active phase and after CS remission. Patients may not talk spontaneously about psychiatric symptoms they present, thus clinicians should ask directly about them. We recommend the use of screening tools in clinical practice to detect and treat these symptoms promptly. Even if reference endocrinologists cannot perform a definite psychiatric diagnosis, it will be important to ask patients directly about the presence of symptoms and refer if necessary to a psychiatrist. Additionally, patient information and educational programmes could be useful to manage psychiatric symptoms and to improve quality of life in patients with CS.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28393326     DOI: 10.1007/s40265-017-0735-z

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  89 in total

Review 1.  Glucocorticoid hedgehog agonists in neurogenesis.

Authors:  Jiangbo Wang; Larry S Barak; Robert A Mook; Wei Chen
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

2.  Case of isolated adrenocorticotropic hormone deficiency mimicking major depressive disorder.

Authors:  Yasutaka Tatsuzawa; Yousuke Ono; Tomohisa Takahashi; Aihide Yoshino; Soichiro Nomura
Journal:  Psychiatry Clin Neurosci       Date:  2011-04       Impact factor: 5.188

3.  Improvement in mood and ideation associated with increase in right caudate volume.

Authors:  Monica N Starkman; Bruno Giordani; Stephen S Gebarski; David E Schteingart
Journal:  J Affect Disord       Date:  2006-12-15       Impact factor: 4.839

4.  Occult Cushing's disease presenting with acute psychosis.

Authors:  M F Saad; F Adams; B Mackay; N G Ordonez; M E Leavens; N A Samaan
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

5.  The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics.

Authors:  Elena Valassi; Alicia Santos; Maria Yaneva; Miklós Tóth; Christian J Strasburger; Philippe Chanson; John A H Wass; Olivier Chabre; Marija Pfeifer; Richard A Feelders; Stylianos Tsagarakis; Peter J Trainer; Holger Franz; Kathrin Zopf; Sabina Zacharieva; Steven W J Lamberts; Antoine Tabarin; Susan M Webb
Journal:  Eur J Endocrinol       Date:  2011-06-29       Impact factor: 6.664

6.  Long-term cognitive impairments and attentional deficits in patients with Cushing's disease and cortisol-producing adrenal adenoma in remission.

Authors:  Oskar Ragnarsson; Peter Berglund; Derek N Eder; Gudmundur Johannsson
Journal:  J Clin Endocrinol Metab       Date:  2012-07-03       Impact factor: 5.958

7.  Treatment of severe psychosis due to ectopic Cushing's syndrome.

Authors:  Y M Bilgin; H E van der Wiel; H R Fischer; W W De Herder
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

8.  Cardiovascular risk and white matter lesions after endocrine control of Cushing's syndrome.

Authors:  Alicia Santos; Eugenia Resmini; Beatriz Gómez-Ansón; Iris Crespo; Esther Granell; Elena Valassi; Patricia Pires; Yolanda Vives-Gilabert; M Antonia Martínez-Momblán; Manuel de Juan; Maria Mataró; Susan M Webb
Journal:  Eur J Endocrinol       Date:  2015-12       Impact factor: 6.664

9.  Quality of life after laparoscopic bilateral adrenalectomy for Cushing's disease.

Authors:  Mary T Hawn; David Cook; Clifford Deveney; Brett C Sheppard
Journal:  Surgery       Date:  2002-12       Impact factor: 3.982

10.  Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing's disease: a case-control study.

Authors:  Cornelie D Andela; Steven J A van der Werff; J Nienke Pannekoek; Susan M van den Berg; Onno C Meijer; Mark A van Buchem; Serge A R B Rombouts; Roos C van der Mast; Johannes A Romijn; Jitske Tiemensma; Nienke R Biermasz; Nic J A van der Wee; Alberto M Pereira
Journal:  Eur J Endocrinol       Date:  2013-10-21       Impact factor: 6.664

View more
  12 in total

Review 1.  Quality of life impairment after a diagnosis of Cushing's syndrome.

Authors:  Susan M Webb; Elena Valassi
Journal:  Pituitary       Date:  2022-06-29       Impact factor: 3.599

2.  Problem-solving therapy can reduce psychological distress in patients with Cushing's disease: a randomized controlled trial.

Authors:  Cem Sulu; Gamze Karadayi Kaynak; Tolga Koskun; Oguzhan Koca; Tevhide Betul Icli; Yasin Kavla; Hande Mefkure Ozkaya; Senol Turan; Mehmet Eskin; Pinar Kadioglu
Journal:  Pituitary       Date:  2022-09-01       Impact factor: 3.599

3.  Lack of functional remission in Cushing's syndrome.

Authors:  M Vermalle; M Alessandrini; T Graillon; N C Paladino; K Baumstarck; F Sebag; H Dufour; T Brue; F Castinetti
Journal:  Endocrine       Date:  2018-07-17       Impact factor: 3.633

Review 4.  Psychiatric Symptoms in Cushing's Syndrome: A Systematic Review.

Authors:  Tiffany Y Lin; Jasmine Hanna; Waguih William Ishak
Journal:  Innov Clin Neurosci       Date:  2020-01-01

Review 5.  Quality of Life in Patients With Cushing's Disease.

Authors:  Alicia Santos; Eugenia Resmini; Mª Antonia Martínez Momblán; Elena Valassi; Luciana Martel; Susan M Webb
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-11       Impact factor: 5.555

Review 6.  Health-Related Quality of Life in Adrenocortical Carcinoma.

Authors:  Rebecca V Steenaard; Laura A Michon; Harm R Haak
Journal:  Cancers (Basel)       Date:  2019-10-08       Impact factor: 6.639

7.  ARE THERE RELIABLE PREDICTORS FOR THE IMPAIRED QUALITY OF LIFE IN PATIENTS WITH CUSHING'S SYNDROME?

Authors:  A B Nankova; M Yaneva; A Elenkova; K Kalinov; S Zacharieva
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

8.  Development and evaluation of a health-related quality-of-life tool for dogs with Cushing's syndrome.

Authors:  Imogen Schofield; Dan G O'Neill; Dave C Brodbelt; David B Church; Rebecca F Geddes; Stijn J M Niessen
Journal:  J Vet Intern Med       Date:  2019-10-29       Impact factor: 3.333

9.  Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.

Authors:  Eliza B Geer; Roberto Salvatori; Atanaska Elenkova; Maria Fleseriu; Rosario Pivonello; Przemyslaw Witek; Richard A Feelders; Marie Bex; Stina W Borresen; Soraya Puglisi; Beverly M K Biller; Fredric Cohen; Francesca Pecori Giraldi
Journal:  Pituitary       Date:  2020-11-20       Impact factor: 4.107

10.  Psychotropic Drugs in Patients with Cushing's Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study.

Authors:  Daniel Bengtsson; Oskar Ragnarsson; Katarina Berinder; Per Dahlqvist; Britt Edén Engström; Bertil Ekman; Charlotte Höybye; Pia Burman; Jeanette Wahlberg
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.